New conference and laboratory facility to showcase the company's product portfolio and serve as a research and training hub to advance biopreservation and cell processing innovation BOTHELL, Wash. , Nov. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced the opening of the Aby J.... Read More

BOTHELL, Wash. , Nov. 17, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) market, today announced that management will participate in the following investor conferences during November and December: Raymond James Napa Small Cap Symposium November 17, 2025 Napa Valley at The Meritage Stephens Annual... Read More

Cell Processing revenue of $25.4 million , up 33% over Q3 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 64% GAAP net income of $0.6 million and non-GAAP adjusted EBITDA of $7.8 million or 28% of revenue Raises 2025 full-year Cell Processing revenue guidance to $93.0 million - $94.0 million ; Full-year total revenue guidance to $95.0 - $96.0 million , adjusted for the recent sale of its evo cold chain... Read More

BOTHELL, Wash. , Oct. 23, 2025 /PRNewswire/ -- BioLife Solutions, Inc . (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's third quarter 2025 financial results will be released after market close on Thursday, November 6, 2025 . The Company will host a conference call and live webcast at 4:30pm ET ( 1:30pm PT )... Read More

BOTHELL, Wash. , Oct. 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools for the cell and gene therapy ("CGT") market, announces the sale of SAVSU Cleo Technologies, LLC. (f/k/a SAVSU Technologies, Inc.) ("SAVSU"), its wholly owned cold chain logistics subsidiary, for $25.5 million (subject to certain adjustments) in cash to... Read More

Cell Processing revenue of $23.0 million , up 28% over Q2 2024 GAAP gross margin of 62% and non-GAAP adjusted gross margin of 65% GAAP net loss of $15.8 million , inclusive of a non-cash $15.5 million IPR&D expense, and non-GAAP adjusted EBITDA of $6.1 million or 24% of revenue Raises full-year 2025 revenue guidance to $100.0 million - $103.0 million , and full-year 2025 Cell Processing revenue guidance to $91.0 million -... Read More

BOTHELL, Wash. , July 28, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced that as part of a larger round of financing it has purchased $2 million of convertible notes in Pluristyx, Inc. ("Pluristyx"), a Seattle based developer of innovative induced pluripotent stem cell (iSPC)... Read More

BOTHELL, Wash. , July 24, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's second quarter 2025 financial results will be released after market close on Thursday, August 7, 2025 . The Company will host a conference call and live webcast at 4:30pm ET ( 1:30pm PT ) that... Read More

BOTHELL, Wash. , May 14, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22 nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissance Hotel Benchmark 2025... Read More

BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET . If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if... Read More

Cell Processing revenue of $21.6 million , up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of... Read More

BOTHELL, Wash. , April 30, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the Company's first quarter 2025 financial results will be released after market close on Thursday, May 8, 2025 . The Company will host a conference call and live webcast at 4:30pm ET ( 1:30pm PT ) that... Read More

Strategic acquisition enhances biopreservation media portfolio with novel Ice Recrystallization Inhibitor technology Marks the second acquisition from Bioproduction Innovation Accelerator program BOTHELL, Wash. , April 7, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT")... Read More

BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven. Ms. Coste will serve as chair of the audit committee, replacing Joydeep Goswami , who will... Read More

Cell Processing revenue up 7% sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12% over prior year to $73.5 million GAAP gross margin of 60% and non-GAAP adjusted gross margin of 63% for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million , or 18% of total revenue for the fourth quarter Expects 2025 Cell Processing... Read More

BOTHELL, Wash. , Feb. 20, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the 2024 fourth quarter and full year financial results will be released on March 3, 2025 pre-market. The Company will host a conference call and live webcast at 8:00am ET ( 5:00am PT ) that day. Management... Read More

Fourth quarter Cell Processing revenue increased 7% sequentially to $20.3 million Unaudited revenue for FY2024 from Cell Processing of $73.5 million , exceeded the high end of previously raised guidance BOTHELL, Wash. , Jan. 13, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT)... Read More

BOTHELL, Wash. , Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt , Executive Chairman of Repligen Corporation (Nasdaq: RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective... Read More

Completes the Company's strategic move away from capital equipment businesses BOTHELL, Wash. , Nov. 14, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the sale of its final wholly owned freezer subsidiary, Arctic Solutions, Inc. ("Custom Biogenic Systems" or... Read More

Cell Processing revenue grew 6% sequentially to $19.0 million ; 43% increase compared to 2023 GAAP gross margin of 51% and non-GAAP adjusted gross margin of 54% GAAP net loss from continuing operations of $1.7 million and non-GAAP adjusted EBITDA of $6.1 million or 20% Increasing Cell Processing revenue guidance by $2 million to $72.0 to $73.0 million ; total 2024 revenue guidance of $98.0 million to $100.0 million... Read More

Strategic divestiture heightens focus on proprietary, higher-margin cell processing products All-cash transaction fortifies balance sheet BOTHELL, Wash. , Nov. 12, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market, announces the sale of its wholly owned biostorage... Read More

BOTHELL, Wash. , Oct. 31, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter 2024 financial results will be released after market close on Tuesday, November 12, 2024 . The Company will host a conference call and live webcast at... Read More

Cell Processing revenue increased 11% sequentially to $18.0 million GAAP gross margin of 51% and non-GAAP adjusted gross margin of 52% GAAP net loss from continuing operations of $7.1 million and non-GAAP adjusted EBITDA of $4.8 million or 17% Raising full-year 2024 total revenue guidance to $99.0 million to $101.0 million ; Cell Processing revenue guidance increased to $70.0 million to $71.0 million Conference call begins... Read More

BOTHELL, Wash. , July 25, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter 2024 financial results will be released after market close on Thursday, August 8, 2024 . The Company will host a conference call and live webcast at... Read More

New container developed for the needs of cell and gene therapy (CGT) primary packaging to replace cryopreservation bags with a fracture resistant, rigid construction built for both manual use and closed-system automation. BOTHELL, Wash. , May 29, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier... Read More

Cell Processing revenue increased 10% sequentially to $16.2 million GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , May 9, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer... Read More

BOTHELL, Wash. , April 30, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024 . The Company will host a conference call and live webcast at 4:30pm... Read More

BOTHELL, Wash. , April 18, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") and the broader biopharma markets, today announced that it has completed the divestiture of its wholly owned subsidiary Global Cooling, Inc. ("GCI" or "Stirling"). Roderick de Greef , Chairman and... Read More

BOTHELL, Wash. , March 4, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that Roderick de Greef , Chief Executive Officer, and Troy Wichterman, Chief Financial Officer, will present and meet with current and prospective investors at the following March... Read More

Fourth quarter Cell Processing revenue up 11% sequentially to $14.8 million , and positive adjusted EBITDA of $700,000 Expects 2024 revenue of $95.5 - $100.0 million excluding freezer business and positive adjusted EBITDA Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , Feb. 29, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of... Read More

BOTHELL, Wash. , Feb. 20, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2023 financial results will be released after market close on Thursday, February 29, 2024 . The Company will host a conference call and live... Read More

Fourth quarter Cell Processing revenue increased 11% sequentially to $14.8 million BOTHELL, Wash. , Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.... Read More

Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , Nov. 9, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results for the third quarter and nine months of 2023. "It's been... Read More

BOTHELL, Wash. , Nov. 2, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's third quarter financial results will be released after market close on Thursday, November 9, 2023 . The Company will host a conference call and live webcast at 4:30pm ET... Read More

Roderick de Greef appointed Chairman and Chief Executive Officer bringing 20+ years of prior BioLife experience Garrie Richardson appointed Chief Revenue Officer Preliminary Q3 revenue of $33.3 million and expect 2023 revenue at the low end of the previously announced guidance range BOTHELL, Wash. , Oct. 19, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools... Read More

Committed to Divesting Stirling Ultracold and Custom Biogenic Systems by End of 2023 Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , Aug. 8, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, today announced financial results... Read More

BOTHELL, Wash. , July 27, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's second quarter financial results will be released after market close on Tuesday, August 8, 2023 . The Company will host a conference call and live webcast at 4:30pm ET (... Read More

BOTHELL, Wash. , June 14, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced that all of its SciSafe-branded biostorage facilities in the USA have been... Read More

Large-Capacity Tabletop Freezer Expands Line of Controlled-Rate Freezers for Cell and Gene Therapies; Now Available for Order BOTHELL, Wash. , June 6, 2023 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services... Read More

Revenue of $37.7 million increased 4% over Q1 2022, ex-COVID growth of 16% and biopreservation media revenue growth of 28% Q1 2023 Adjusted gross margin improvement; 37% compared to 32% in Q4 2022 Decision to Explore Strategic Alternatives for Ultra-Low Temperature and Cryogenic Freezer Product Lines Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. , May 10, 2023 /PRNewswire/ -- BioLife Solutions , Inc.... Read More

BOTHELL, Wash. , May 2, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's first quarter financial results will be released after market close on Wednesday, May 10, 2023 . The Company will host a conference call and live webcast at 4:30pm ET (... Read More

Record full year revenue of $161.8 million increased 36% over 2021; biopreservation media revenue growth of 45%, validating leading position as a critical cell and gene therapies (CGT) tools and services supplier Record Q4 2022 revenue of $44.3 million increased 19% over 2021; biopreservation media revenue growth of 35% Full year adjusted EBITDA of $3.6 million and Q4 2022 adjusted EBITDA of $1.7 million Conference call... Read More

BOTHELL, Wash. , March 10, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today provided commentary on its current banking relationship with Silicon Valley Bank ("SVB"). BioLife is monitoring the situation at SVB carefully and does not believe there is any current risk to... Read More

BOTHELL, Wash. , March 9, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced the Company's fourth quarter and full year 2022 financial results will be released after market close on Thursday, March 16, 2023 . The Company will host a conference call and live... Read More

Exclusive global supplier of non-toxic, non-flammable PCM; first to operate at -70°C, meeting critical temperature requirement of biologic materials. BOTHELL, Wash. , March 1, 2023 /PRNewswire/ -- BioLife Solutions, Inc . (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and... Read More

BOTHELL, Wash. , Jan. 17, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced the dates of its 2023 analyst day and upcoming investor conferences where management will be presenting and meeting with current and... Read More

Fourth Time Company Recognized in the Last Nine Years BOTHELL, Wash. , Jan. 10, 2023 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced that the Company was recently named as one of Seattle Business magazine's... Read More

Record quarterly revenue of $44.4 million up 19% over Q4 2021 with Cell Processing Platform revenue growth of 37% Record full year revenue of $161.9 million up 36% over 2021, with organic revenue growth of 38% and Cell Processing Platform revenue growth of 53% Initial revenue guidance for 2023 of $188 million to $202 million , reflecting overall growth of 16% to 25% over 2022, and excluding COVID related revenue, growth of... Read More

Announcement Precedes Meetings to be Held During the J.P. Morgan Health Care Conference; Updated Investor Presentation Demonstrates Continued Execution to Drive High-Margin, Recurring Revenue BOTHELL, Wash. , Dec. 19, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today... Read More